Martin MacKay, EVP & Global Head of R&D at ALEXION PHARMACEUTICALS INC (ALXN), sold 8,176 shares at $139.19 ($1.1M) on 2016-05-16, disclosed to the SEC on 2016-05-18.
Seasonal sale ($1.1M) by EVP & Global Head of R&D — this insider has traded ALXN in May in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $139.19 | 4,079 | $568K | 49.9% |
| 2 | $139.19 | 4,079 | $568K | 49.9% |
| 3 | $140.43 | 18 | $3K | 0.2% |
| Total | $139.19 avg | 8,176 | $1.1M | 100% |
| Filing → |
| ALXN | SELL | 2017-02-10 | $28K | — | Filing → |
| ALXN | SELL | 2017-02-08 | $684K | — | Filing → |
| ALXN | SELL | 2016-03-01 | $139K | — | Filing → |